FR2329276B1 - - Google Patents

Info

Publication number
FR2329276B1
FR2329276B1 FR7533084A FR7533084A FR2329276B1 FR 2329276 B1 FR2329276 B1 FR 2329276B1 FR 7533084 A FR7533084 A FR 7533084A FR 7533084 A FR7533084 A FR 7533084A FR 2329276 B1 FR2329276 B1 FR 2329276B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7533084A
Other languages
French (fr)
Other versions
FR2329276A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR7533084A priority Critical patent/FR2329276A1/fr
Priority to SE7610859A priority patent/SE430502B/xx
Priority to NLAANVRAGE7611576,A priority patent/NL187102C/xx
Priority to US05/734,557 priority patent/US4097578A/en
Priority to SU762414002A priority patent/SU596165A3/ru
Priority to ES452746A priority patent/ES452746A1/es
Priority to LU76085A priority patent/LU76085A1/xx
Priority to CA264,606A priority patent/CA1086751A/fr
Priority to BE171876A priority patent/BE847742A/xx
Priority to DK487476A priority patent/DK152125C/da
Priority to AU19095/76A priority patent/AU500542B2/en
Priority to DE2649925A priority patent/DE2649925C2/de
Priority to IE2419/76A priority patent/IE43875B1/en
Priority to GB45034/76A priority patent/GB1518444A/en
Priority to CH1369176A priority patent/CH599164A5/de
Priority to JP51129586A priority patent/JPS6011701B2/ja
Publication of FR2329276A1 publication Critical patent/FR2329276A1/fr
Application granted granted Critical
Publication of FR2329276B1 publication Critical patent/FR2329276B1/fr
Priority to LU88282C priority patent/LU88282I2/fr
Priority to NL930079C priority patent/NL930079I2/nl
Priority to GEAP19931536A priority patent/GEP19970948B/en
Priority to BG98507A priority patent/BG60533B2/bg
Priority to MD94-0279A priority patent/MD246C2/ro
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electromechanical Clocks (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR7533084A 1975-01-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant Granted FR2329276A1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
SE7610859A SE430502B (sv) 1975-10-29 1976-09-30 Sett att framstella nya substituerade imidazolidiner
NLAANVRAGE7611576,A NL187102C (nl) 1975-10-29 1976-10-20 Werkwijze voor de bereiding van een farmaceutisch preparaat dat een 2-fenylimidazolidinon bevat, gevormd preparaat verkregen met deze werkwijze, alsmede werkwijze voor de bereiding van imidazolidinonen.
US05/734,557 US4097578A (en) 1975-10-29 1976-10-21 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl imidazolidines
SU762414002A SU596165A3 (ru) 1975-10-29 1976-10-21 Способ получени имидазолидинов
ES452746A ES452746A1 (es) 1975-10-29 1976-10-27 Procedimiento de preparacion de nuevas imidazolidinas.
AU19095/76A AU500542B2 (en) 1975-01-29 1976-10-28 Imidazlidine derivatives and pharmaceutical compositions containing same which have antiandrogenic activity
CA264,606A CA1086751A (fr) 1975-10-29 1976-10-28 Procede de preparation de nouvelles imidazolidines substituees
BE171876A BE847742A (fr) 1975-10-29 1976-10-28 Nouvelles imidazolidines, procede de preparation et compositions pharmaceutiques
DK487476A DK152125C (da) 1975-10-29 1976-10-28 Analogifremgangsmaade til fremstilling af 1-(3'-trifluormethyl-4'-nitrophenyl)-4,4-dimethylimidazolidin-2,5-dion
LU76085A LU76085A1 (US07655688-20100202-C00374.png) 1975-10-29 1976-10-28
DE2649925A DE2649925C2 (de) 1975-10-29 1976-10-29 5,5-Dimethyl-3-[4-nitro-3-(trifluormethyl)-phenyl]-2-imidazolidinone, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
IE2419/76A IE43875B1 (en) 1975-10-29 1976-10-29 N-phenyl-imidazolidine derivatives,processes for preparing them and pharmaceutical compositions containing them
GB45034/76A GB1518444A (en) 1975-10-29 1976-10-29 N-phenyl-imidazolidine derivatives processes for preparing them and pharmaceutical compositions containing them
CH1369176A CH599164A5 (US07655688-20100202-C00374.png) 1975-10-29 1976-10-29
JP51129586A JPS6011701B2 (ja) 1975-10-29 1976-10-29 新規なイミダゾリンジン類、それらの製造法及び製薬組成物
LU88282C LU88282I2 (fr) 1975-10-29 1993-06-03 Anandron
NL930079C NL930079I2 (nl) 1975-10-29 1993-06-17 Werkwijze voor de bereiding van een farmaceutisch preparaat dat een 2-fenylimidazolidinon bevat, gevormd preparaat verkregen met deze werkwijze alsmede werkwijze voor de bereiding van imidazolidinonen.
GEAP19931536A GEP19970948B (en) 1975-10-29 1993-09-09 Method for Production of Imidazolidine
BG98507A BG60533B2 (bg) 1975-10-29 1994-02-22 Заместени имидазолидини,метод за получаването ими приложението им като лекарствено средство и състави,които ги съдържат
MD94-0279A MD246C2 (ro) 1975-10-29 1994-09-08 Procedeu de obţinere a imidazolidinelor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (2)

Publication Number Publication Date
FR2329276A1 FR2329276A1 (fr) 1977-05-27
FR2329276B1 true FR2329276B1 (US07655688-20100202-C00374.png) 1979-09-14

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7533084A Granted FR2329276A1 (fr) 1975-01-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Country Status (18)

Country Link
US (1) US4097578A (US07655688-20100202-C00374.png)
JP (1) JPS6011701B2 (US07655688-20100202-C00374.png)
AU (1) AU500542B2 (US07655688-20100202-C00374.png)
BE (1) BE847742A (US07655688-20100202-C00374.png)
BG (1) BG60533B2 (US07655688-20100202-C00374.png)
CA (1) CA1086751A (US07655688-20100202-C00374.png)
CH (1) CH599164A5 (US07655688-20100202-C00374.png)
DE (1) DE2649925C2 (US07655688-20100202-C00374.png)
DK (1) DK152125C (US07655688-20100202-C00374.png)
ES (1) ES452746A1 (US07655688-20100202-C00374.png)
FR (1) FR2329276A1 (US07655688-20100202-C00374.png)
GB (1) GB1518444A (US07655688-20100202-C00374.png)
GE (1) GEP19970948B (US07655688-20100202-C00374.png)
IE (1) IE43875B1 (US07655688-20100202-C00374.png)
LU (2) LU76085A1 (US07655688-20100202-C00374.png)
NL (2) NL187102C (US07655688-20100202-C00374.png)
SE (1) SE430502B (US07655688-20100202-C00374.png)
SU (1) SU596165A3 (US07655688-20100202-C00374.png)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655688B2 (en) 2001-02-27 2010-02-02 Bristol-Myers Squibb Company Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7655689B2 (en) 2000-06-28 2010-02-02 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
IL55774A (en) * 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
FI801184A (fi) * 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
JPH0680016B2 (ja) * 1984-08-02 1994-10-12 ラブリ−，フエルナンド ホルモン依存性がんの併用治療のための医薬組成物
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2706456B1 (fr) 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
CZ20024214A3 (cs) * 2000-06-28 2003-04-16 Bristol-Myers Squibb Company Selektivní androgen receptorový modulátor, způsob jeho identifikace, jeho konstrukce a použití
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US7015253B2 (en) * 2001-07-10 2006-03-21 American Medical Systems, Inc. Regimen for treating prostate tissue and surgical kit for use in the regimen
DE60228330D1 (de) * 2001-12-19 2008-09-25 Bristol Myers Squibb Co Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
AU2004293013B2 (en) 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005060661A2 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) * 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2006031715A2 (en) * 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX346924B (es) 2005-05-13 2017-04-05 Univ California Compuestos de diarilhidantoina.
NZ560354A (en) 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
HUE042037T2 (hu) 2006-03-27 2019-06-28 Univ California Androgén receptormodulátor a prosztatarák és az androgén receptorral összefüggõ betegségek kezeléséhez
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP3510959B1 (en) * 2007-01-02 2021-03-03 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
WO2009111736A1 (en) 2008-03-06 2009-09-11 Aquabeam Llc Tissue ablation and cautery with optical energy carried in fluid stream
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
PT3124481T (pt) 2010-02-16 2018-06-18 Aragon Pharmaceuticals Inc Moduladores do receptor de androgénios e suas utilizações
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2819599B1 (en) 2012-02-29 2018-05-23 Procept Biorobotics Corporation Automated image-guided tissue resection and treatment
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP6403695B2 (ja) 2013-02-14 2018-10-10 プロセプト バイオロボティクス コーポレイション アクアアブレーションアクアビーム眼科手術方法および装置
ES2798899T3 (es) 2013-02-25 2020-12-14 Novartis Ag Mutación novedosa del receptor de andrógenos
BR112016005036A2 (pt) 2013-09-06 2020-04-07 Procept Biorobotics Corp aparelho para ressecção de tecido guiada por imagem automatizada
JP6651471B2 (ja) 2014-06-30 2020-02-19 プロセプト バイオロボティクス コーポレイション 流体ジェット組織アブレーションおよび冷凝固（ａｑｕａｂｌａｔｉｏｎ）方法および装置
BR112017004431B1 (pt) 2014-09-05 2022-11-01 Procept Biorobotics Corporation Aparelho para tratar um paciente
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3036011A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (US07655688-20100202-C00374.png) * 1970-05-28 1974-05-29
JPS5136332B1 (US07655688-20100202-C00374.png) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655689B2 (en) 2000-06-28 2010-02-02 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7655688B2 (en) 2001-02-27 2010-02-02 Bristol-Myers Squibb Company Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
DK152125B (da) 1988-02-01
JPS6011701B2 (ja) 1985-03-27
GEP19970948B (en) 1997-04-18
SE7610859L (sv) 1977-04-30
NL187102C (nl) 1991-06-03
DK487476A (da) 1977-04-30
NL930079I1 (nl) 1993-09-16
JPS5257176A (en) 1977-05-11
DE2649925C2 (de) 1986-08-28
SE430502B (sv) 1983-11-21
DK152125C (da) 1988-06-20
IE43875L (en) 1977-04-29
CA1086751A (fr) 1980-09-30
AU500542B2 (en) 1979-05-24
NL7611576A (nl) 1977-05-03
CH599164A5 (US07655688-20100202-C00374.png) 1978-05-12
NL187102B (nl) 1991-01-02
FR2329276A1 (fr) 1977-05-27
SU596165A3 (ru) 1978-02-28
GB1518444A (en) 1978-07-19
LU88282I2 (fr) 1994-05-04
DE2649925A1 (de) 1977-05-12
ES452746A1 (es) 1977-10-01
US4097578A (en) 1978-06-27
NL930079I2 (nl) 1993-10-01
LU76085A1 (US07655688-20100202-C00374.png) 1977-05-31
AU1909576A (en) 1978-05-04
BE847742A (fr) 1977-04-28
IE43875B1 (en) 1981-06-17
BG60533B2 (bg) 1995-07-28

Similar Documents

Publication Publication Date Title
FR2329276B1 (US07655688-20100202-C00374.png)
JPS5231077U (US07655688-20100202-C00374.png)
JPS5349025Y2 (US07655688-20100202-C00374.png)
AU480151B2 (US07655688-20100202-C00374.png)
JPS5737063B2 (US07655688-20100202-C00374.png)
JPS5242060U (US07655688-20100202-C00374.png)
JPS5238441U (US07655688-20100202-C00374.png)
JPS5181745A (US07655688-20100202-C00374.png)
JPS5313912Y2 (US07655688-20100202-C00374.png)
FR2306995B1 (US07655688-20100202-C00374.png)
JPS5145246Y1 (US07655688-20100202-C00374.png)
JPS51111476U (US07655688-20100202-C00374.png)
JPS51122476U (US07655688-20100202-C00374.png)
JPS51123124U (US07655688-20100202-C00374.png)
JPS51105112U (US07655688-20100202-C00374.png)
JPS51157250U (US07655688-20100202-C00374.png)
IN145147B (US07655688-20100202-C00374.png)
CH376676A4 (US07655688-20100202-C00374.png)
CH586413B5 (US07655688-20100202-C00374.png)
CH201875A4 (US07655688-20100202-C00374.png)
BG22526A1 (US07655688-20100202-C00374.png)
BG22319A1 (US07655688-20100202-C00374.png)
BG22272A1 (US07655688-20100202-C00374.png)
BG22115A1 (US07655688-20100202-C00374.png)
CH577352A5 (US07655688-20100202-C00374.png)

Legal Events

Date Code Title Description
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0241, 920521

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0241, 751029

CL Concession to grant licences